J. Lahmar

2.2k total citations
15 papers, 340 citations indexed

About

J. Lahmar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, J. Lahmar has authored 15 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 4 papers in Immunology. Recurrent topics in J. Lahmar's work include Cancer Immunotherapy and Biomarkers (12 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Research Studies (4 papers). J. Lahmar is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Research Studies (4 papers). J. Lahmar collaborates with scholars based in France, Spain and Italy. J. Lahmar's co-authors include Benjamin Besse, Caroline Caramella, David Planchard, Laura Mezquita, Roberto Ferrara, Anas Gazzah, Jean‐Charles Soria, Samy Ammari, Aurélien Marabelle and Corinne Balleyguier and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

J. Lahmar

15 papers receiving 335 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Lahmar France 7 305 194 72 66 31 15 340
Mélodie Tazdait France 4 229 0.8× 138 0.7× 51 0.7× 64 1.0× 26 0.8× 7 276
Grant Toland United States 3 310 1.0× 194 1.0× 59 0.8× 30 0.5× 55 1.8× 5 347
Catherine Dubos‐Arvis France 8 310 1.0× 348 1.8× 27 0.4× 104 1.6× 49 1.6× 11 476
Lyudmila Zhukova Russia 7 201 0.7× 122 0.6× 38 0.5× 35 0.5× 70 2.3× 89 287
Virginia Palomar Coloma France 4 421 1.4× 190 1.0× 118 1.6× 30 0.5× 48 1.5× 5 481
Miao Huang China 9 184 0.6× 159 0.8× 50 0.7× 33 0.5× 44 1.4× 17 298
Brad Wasserman United States 7 347 1.1× 144 0.7× 104 1.4× 29 0.4× 89 2.9× 10 418
Catherine Wadsworth United States 10 434 1.4× 411 2.1× 74 1.0× 60 0.9× 37 1.2× 18 554
Aaron E. Sosa Spain 8 194 0.6× 84 0.4× 48 0.7× 27 0.4× 30 1.0× 13 275
Bharathi Vennapusa United States 6 237 0.8× 106 0.5× 66 0.9× 20 0.3× 69 2.2× 15 312

Countries citing papers authored by J. Lahmar

Since Specialization
Citations

This map shows the geographic impact of J. Lahmar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Lahmar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Lahmar more than expected).

Fields of papers citing papers by J. Lahmar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Lahmar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Lahmar. The network helps show where J. Lahmar may publish in the future.

Co-authorship network of co-authors of J. Lahmar

This figure shows the co-authorship network connecting the top 25 collaborators of J. Lahmar. A scholar is included among the top collaborators of J. Lahmar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Lahmar. J. Lahmar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Ferrara, Roberto, Laura Mezquita, Matthieu Texier, et al.. (2019). Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).. Journal of Clinical Oncology. 37(15_suppl). 9107–9107. 13 indexed citations
2.
Ferrara, Roberto, Caroline Caramella, Matthieu Texier, et al.. (2017). Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO). Annals of Oncology. 28. v464–v465. 19 indexed citations
3.
Mezquita, Laura, Mélinda Charrier, Édouard Auclin, et al.. (2017). P3.02c-065 Neutrophil-To-Lymphocyte and Other Ratios as Prognostic and Predictive Markers of Immune Checkpoint Inhibitors in Advanced NSCLC Patients. Journal of Thoracic Oncology. 12(1). S1315–S1316. 2 indexed citations
4.
Mezquita, Laura, Édouard Auclin, Mélinda Charrier, et al.. (2017). The Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients. Annals of Oncology. 28. v473–v473. 5 indexed citations
5.
Mezquita, Laura, Édouard Auclin, Roberto Ferrara, et al.. (2017). Baseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. Annals of Oncology. 28. v472–v472. 12 indexed citations
6.
Tazdait, Mélodie, Laura Mezquita, J. Lahmar, et al.. (2017). Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. European Journal of Cancer. 88. 38–47. 244 indexed citations
7.
Caramella, Caroline, Mélodie Tazdait, Laura Mezquita, et al.. (2017). Patterns of progression under antiPD1/PDL1 in advanced NSCLC patients allow discriminating pseudo-progression from real progression. Annals of Oncology. 28. v413–v413. 3 indexed citations
8.
Mezquita, Laura, Édouard Auclin, Sylvestre Le Moulec, et al.. (2017). Pathological evaluation of tumor infiltrating lymphocytes and the benefit of nivolumab in advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. v30–v30. 4 indexed citations
9.
Mazza, Camille, Julia Arfi‐Rouche, Serge Koscielny, et al.. (2017). Effect of nivolumab on tumor growth rate (TGR) in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 35(6_suppl). 481–481. 2 indexed citations
10.
Mezquita, Laura, Édouard Auclin, Roberto Ferrara, et al.. (2017). Baseline-derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) to predict the benefit of immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology. 35(15_suppl). 9089–9089. 4 indexed citations
11.
Henon, Clémence, Laura Mezquita, Édouard Auclin, et al.. (2017). P2.07-005 Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology. 12(11). S2417–S2417. 9 indexed citations
12.
Mezquita, Laura, Édouard Auclin, Mélinda Charrier, et al.. (2017). MA 05.03 The Early Monitoring of Derived Neutrophil-To Lymphocyte Ratio (dNLR) Could Be a Surrogate Marker of Benefit of Immunotherapy in NSCLC. Journal of Thoracic Oncology. 12(11). S1815–S1816. 1 indexed citations
13.
Lahmar, J., Laura Mezquita, Serge Koscielny, et al.. (2016). Immune checkpoint inhibitors (IC) induce paradoxical progression in a subset of non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi423–vi423. 12 indexed citations
14.
Mezquita, Laura, Mélinda Charrier, J. Lahmar, et al.. (2016). HLA-A2 and immune checkpoints inhibitors in advanced non-small cell lung cancer (NSCLC) patients. Annals of Oncology. 27. vi423–vi423. 1 indexed citations
15.
Lahmar, J., Francesco Facchinetti, Serge Koscielny, et al.. (2016). Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 34(15_suppl). 9034–9034. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mélodie Tazdait Breakdown of academic impact, for papers by Grant Toland Breakdown of academic impact, for papers by Catherine Dubos‐Arvis Breakdown of academic impact, for papers by Lyudmila Zhukova Breakdown of academic impact, for papers by Virginia Palomar Coloma Breakdown of academic impact, for papers by Miao Huang Breakdown of academic impact, for papers by Brad Wasserman Breakdown of academic impact, for papers by Catherine Wadsworth Breakdown of academic impact, for papers by Aaron E. Sosa Breakdown of academic impact, for papers by Bharathi Vennapusa
Rankless by CCL
2026